Blake J. Newman, MD
Dr. Blake Newman is an assistant professor of neurology and an epileptologist who focuses on treating medically refractory epilepsy. He has been on faculty in the epilepsy division since 2016. He currently sees patients at the University of Utah in the Clinical Neurosciences Center. He serves as the fellowship director of the clinical neurophysiology program. In addition, he is the medical director of the Utah Electroneurodiagnostic (END) Institute, a training and educational program for EEG technologists.
Dr. Newman attended the University of Utah as an undergraduate and completed a dual B.S/M.S. program in biomedical engineering. He completed his medical school and residency training at Washington University in St. Louis and Barnes-Jewish Hospital. He then returned to the University of Utah for his fellowship in clinical neurophysiology with an emphasis in EEG and epilepsy. He is ABPN board certified in neurology, clinical neurophysiology, and epilepsy.
Sindhu Richards, MD
Dr. Sindhu Richards is an assistant professor of neurology and an epileptologist who focuses on treating medically refractory epilepsy. She has been on faculty in the epilepsy division since July 2019. She currently sees patients at the University of Utah in the Clinical Neurosciences Center.
Dr. Richards attended the University of Dayton as an undergraduate and completed a BS degree in biochemistry. She then completed her medical school at the University of Cincinnati. She then went on to complete her neurology residency and epilepsy fellowship at University of Hospitals of Cleveland/Case Western. She is ABPN board certified in neurology and epilepsy.
Amir Arain, MD, MPH
Dr. Amir M. Arain is a professor and an epileptologist who focuses on treatment of refractory epilepsy. He graduated from Dow Medical College, Karachi and did his neurology residency and epilepsy fellowship at Vanderbilt University. There he served as faculty of the Department of Neurology as an epileptologist from 2000-2018. He joined University of Utah in July 2018 and currently serves as chief of the Epilepsy Division.
Dr. Arain has been involved in different research projects in epilepsy. He has done several antiepileptic drug trials including levetiracetam, oxcarbazepine, pregabalin, lacosemide, retigabine, brivaracetam, carisbamate, eslicarbazepine, and cenobamate. He has published several peer reviewed research articles and has presented data in different scientific meetings. He has trained more than 100 fellows in epilepsy over the years. His interest is in seizure semiology, SUDEP, disparity of care in epilepsy, and geriatric epilepsy.